NCT04410224View on ClinicalTrials.gov

Study of ASN004 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
Solid Tumor
Interventions
DRUG

ASN004

ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.

Trial Locations (4)

22031

Next Oncology, Fairfax

30322

Winship Cancer Institute of Emory University, Atlanta

78240

NEXT Oncology, San Antonio

78758

NEXT Oncology, Austin

Sponsors
All Listed Sponsors
lead

Kirilys Therapeutics Inc.

INDUSTRY